European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA
- PMID: 34414307
- PMCID: PMC8370061
- DOI: 10.1177/23969873211027006
European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA
Retraction in
-
Withdrawal - Administrative Duplicate Publication.Eur Stroke J. 2022 Mar;7(1):NP1. doi: 10.1177/23969873211059425. Epub 2021 Nov 11. Eur Stroke J. 2022. PMID: 35300249 Free PMC article.
Abstract
Prevention of early recurrent ischaemic stroke remains a priority in people with TIA or ischaemic stroke. A number of trials have recently been completed assessing the efficacy of short-term dual antiplatelet therapy (DAPT) versus single antiplatelet therapy early after minor or moderate stroke or high-risk TIA. We present an Expedited Recommendation for use of dual antiplatelet therapy early after ischaemic stroke and TIA on behalf of the ESO Guideline Board. We make a strong recommendation based on high quality of evidence for use of 21-days of dual antiplatelet therapy with aspirin and clopidogrel in people with a non-cardioembolic minor ischaemic stroke or high-risk TIA in the past 24 hours. We make a weak recommendation based on moderate quality evidence for 30-days of dual antiplatelet therapy with aspirin and ticagrelor in people with non-cardioembolic mild to moderate ischaemic stroke or high-risk TIA in the past 24 hours.
Keywords: Stroke; TIA; antiplatelets.
© European Stroke Organisation 2021.
Comment in
-
Use of dual antiplatelet therapy following posterior ischemic stroke.J Neurol Sci. 2022 Dec 15;443:120486. doi: 10.1016/j.jns.2022.120486. Epub 2022 Nov 2. J Neurol Sci. 2022. PMID: 36368136 No abstract available.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
